Dysfunctional Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma

Blood

Volumn 98, Issue 1, 2001, Pages 146-155

  Van Baarle, Debbie ^a,b,c,d   Hovenkamp, Egbert ^a,b,c   Callan, Margareth F C ^a,b,c   Wolthers, Katja C ^a,b,c   Kostense, Stefan ^a,b,c   Tan, Linda C ^a,b,c   Niesters, Hubert G M ^a,b,c   Osterhaus, Albert D M E ^a,b,c   McMichael, Andrew J ^a,b,c   Van Oers, Marinus H J ^a,b,c   Miedema, Frank ^a,b,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS RELATED COMPLEX; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; NONHODGKIN LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS LOAD;

EID: 0035412391     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.1.146     Document Type: Article

References (47)

1. Miller G. Epstein-Barr virus: biology, pathogenesis and medical aspects. In: Fields BN, Knipe DM, eds. Virology. 2nd ed. New York, NY: Raven Press; 1990:1921-1958.
2. Sixbey JW, Nedrud JG, Raab-Traub N, Hanes RA, Pagano JS. Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med. 1984;310:1225-1230.
3. Rickinson AB. Cellular immunological responses to the virus infection. In: Epstein MA, Achong BG, eds. The Epstein-Barr Virus: Recent Advances. Philadelphia, PA: Lippincott-Raven; 1990:75-115.
4. Speck SH, Chatila T, Flemington E. Reactivation of Epstein-Barr virus: regulation and function of the BZLF1 gene. Trends Microbiol. 1997;5:399-405.
5. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol. 1997;15:405-431.
6. Cohen JI. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine. 1991;70:137-160.
7. Kersten MJ, Van Gorp J, Pals ST, Boon F, Van Oers MHJ. Expression of Epstein-Barr virus latent genes and adhesion molecules in AIDS-related non-Hodgkin's lymphomas: correlation with histology and CD4-cell number. Leuk Lymphoma. 1998;30:515-524.
8. Kersten MJ, Klein MR, Holwerda AM, Miedema F, Van Oers MHJ. EBV-specific cytotoxic T cell responses in HIV-1 infection: different kinetics in patients progressing to opportunistic infection or non-Hodgkin's lymphoma. J Clin Invest. 1997;99:1525-1533.
9. Shibata D, Weiss LM, Hernandez AM, Nathwani BN, Bernstein L, Levine AM. Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus. Blood. 1993;81:2102-2109.
10. Blumberg RS, Paradis T, Byington R, Henle W, Hirsch MS, Schooley RT. Effects of human immunodeficiency virus on the cellular immune response to Epstein-Barr virus in homosexual men: characterization of the cytotoxic response and lymphokine production. J Infect Dis. 1987;155:877-890.
11. Carmichael A, Jin X, Sissons P, Borysiewicz L. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med. 1993;177:249-256.
12. Geretti AM, Dings MEM, Van Els CACM, et al. Human immunodeficiency virus type 1 (HIV-1)-and Epstein-Barr virus-specific cytotoxic T lymphocyte precursors exhibit different kinetics in HIV-1-infected persons. J Infect Dis. 1996;174:34-45.
13. Altman JD, Moss PAH, Goulder PJR, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274:94-96.
14. + memory T cells. J Exp Med. 1997;186:859-865.
15. Bodegain C, Wolf H, Modrow S, Stuber G, Jilg W. Specific cytotoxic T-lymphocytes recognize the immediate-early transactivator ZTA of Epstein-Barr virus. J Virol. 1995;69:4872-4879.
16. Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB. Immediate early and early lytic cycle proteins are frequent targets for the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med. 1997;185:1605-1617.
17. Burrows SR, Sculley TB, Misko IS, Schmidt C, Moss DJ. An Epstein-Barr virus-specific cytotoxic T cell epitope in EBNA3. J Exp Med. 1990;171:345-350.
18. Ogg G, Kostense S, Klein MR, et al. Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific T lymphocytes: correlation with disease progression. J Virol. 1999;73:9153-9160.
19. Kostense S, Ogg GS, Manting EH, et al. High viral burden in the presence of major HIV-specific CD8+ T cell expansions: evidence for impaired T cell effector function. Eur J Immunol. 2001;31:677-686.
20. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noorda J. A rapid and simple method for purification of nucleic acids. J Clin Microbiol. 1990;28:495-503.
21. Cameron KR, Stamminger T, Craxton M, Bodemer W, Honess RW, Fleckenstein B. The 160,000-Mr virion protein encoded at the right end of the herpesvirus saimiri genome is homologous to the 140,000-Mr membrane antigen encoded at the left end of the Epstein-Barr virus genome. J Virol. 1987;61:2063-2070.
22. Meyohas MC, Marechal V, Desire N, Bouillie J, Frottier J, Nicolas JC. Study of mother-to-child Epstein-Barr virus transmission by means of nested PCRs. J Virol. 1996;70:6816-6819.
23. Niesters HGM, van Esser J, Fries E, Wolthers KC, Cornelissen J, Osterhaus ADME. The development of a high-throughput real-time quantitative assay for Epstein-Barr virus detection. J Clin Microbiol. 2000;38:712-715.
24. Klein MR, Van der Burg SH, Hovenkamp E, et al. Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses. J Gen Virol. 1998;79:2191-2201.
25. Matloubian M, Concepcion RJ, Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol. 1994;68:8056-8063.
26. Battegay M, Moskophidis D, Rahemtulla A, Hengartner H, Mak TW, Zinkernagel RM. Enhanced establishment of a virus carrier state in adult CD4+ T-cell deficient mice. J Virol. 1994;68:4700-4704.
27. Zajac AJ, Blattman JN, Murali-Krishna K, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 1998;188:2205-2213.
28. von Herrath MG, Yokoyama M, Dockter J, Oldstone MBA, Whitton JL. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J Virol. 1996;70:1072-1079.
29. Cardin RD, Brooks JW, Sarawar SR, Doherty PC. Progressive loss of the CD8+ T cell-mediated control of a g-Herpesvirus in the absence of CD4+ T cells. J Exp Med. 1996;184:863-871.
30. Hasenkrug KJ, Brooks DM, Dittmer U. Critical role for CD4(+) T cells in controlling retrovirus replication and spread in persistently infected mice. J Virol. 1998;72:6559-6564.
31. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-1044.
32. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92:1549-1555.
33. Brodie SJ, Lewinsohn DA, Patterson BK, et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med. 1999;5:34-41.
34. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1 specific CD4+ T cell responses associated with control of viremia. Science. 1997;278:1447-1450.
35. Pontesilli O, Carotenuto P, Kerkhof-Garde SR, et al. Lymphoproliferative response to HIV-1 p24 in long-term survivors of HIV-1 infection is predictive of persistent AIDS-free infection. AIDS Res Hum Retroviruses. 1999;15:973-981.
36. Klein MR, Van Baalen CA, Holwerda AM, et al. Kinetics of Gag-specific CTL responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med. 1995;181:1365-1372.
37. Rinaldo CR, Huang XL, Fan Z, et al. High levels of antihuman immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1 infected long-term nonprogressors. J Virol. 1995;69:5838-5842.
38. Pitcher CJ, Quittner C, Peterson DM, et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med. 1999;5:518-525.
39. Kalams SA, Buchbinder SP, Rosenberg ES, et al. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol. 1999;73:6715-6720.
40. + T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med. 1999;187:1395-1402.
41. Tan LC, Gudgeon N, Annels NE, et al. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol. 1999;162:1827-1835.
42. Meyaard L, Otto SA, Jonker RR, Mijnster MJ, Keet RPM, Miedema F. Programmed death of T cells in HIV-1 infection. Science. 1992;257:217-219.
43. Meyaard L, Otto SA, Keet IP, Roos MT, Miedema F. Programmed death of T cells in HIV-1 infection: no correlation with progression to disease. J Clin Invest. 1994;93:982-988.
44. Slifka MK, Rodriguez F, Whitton JL. Rapid on/off cycling of cytokine production by virus-specific CD8+ T cells. Nature. 1999;401:76-79.
45. Lechner F, Wong DK, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med. 2000;191:1499-1512.
46. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999;5:677-685.
47. Appay V, Nixon DF, Donahoe SM, et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med. 2000;192:63-76.